-+ 0.00%
-+ 0.00%
-+ 0.00%

EMA : RECOMMENDS MARKETING AUTHORISATION FOR FOUNDAYO (ORFORGLIPRON) ORAL GLP-1 FOR WEIGHT MANAGEMENT AND TYPE 2 DIABETES

Reuters·10/16/2026 10:10:01